JoshiJAlumkalMD

Oncology • Ann Arbor, MI

Genitourinary Oncology, Hematologic Oncology

Leader of the Prostate and Genitourinary Medical Oncology Section; Professor of Internal Medicine, University of Michigan Medical Center

Join to view full profile

Dr. Alumkal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Alumkal's full profile

Already have an account?

Office
1500 E Medical Center Dr
Rogel Cancer Center
Ann Arbor, MI 48109

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2002 - 2006
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1998 - 2002
Baylor College of MedicineClass of 1998

Certifications & Licensure

MI State Medical License 2019 - 2026
OR State Medical License 2006 - 2021
MD State Medical License 2002 - 2008
TX State Medical License 2000 - 2006
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration Start of enrollment: 2009 Jun 01
Completed
Phase 1, Phase 2
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy Start of enrollment: 2014 Feb 05
Active, not recruiting
Phase 2
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide Start of enrollment: 2013 Mar 12
Completed

Publications & Presentations

PubMed

2 citations
An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression.
Raunak Shrestha, Lisa N Chesner, Meng Zhang, Stanley Zhou, Adam Foye
Cancer Research. 2024-09-16
1 citations
Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer.
Shuang G Zhao, Matthew Bootsma, Stanley Zhou, Raunak Shrestha, Thaidy Moreno-Rodriguez
Nature Genetics. 2024-08-01
1 citations
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression.
Meng Zhang, Martin Sjöström, Xiekui Cui, Adam Foye, Kyle Farh
Nature Cell Biology. 2024-07-01

Journal Articles

Maintenance and Pharmacologic Targeting of ROR1 Protein Levels via UHRF1 in T(1;19) Pre-B-ALL
Joshi Alumkal, MD, Nature

Press Mentions

Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021
BET Inhibitors May Help Overcome a Newly Recognized Form of Resistance to Prostate Cancer DrugsJune 20th, 2021
BET Inhibitors Show Promise in Overcoming Lineage Plasticity, a Newly Recognized Form of Resistance to Prostate Cancer DrugsJune 18th, 2021
Join now to see all

Professional Memberships

American College of Physicians - ACP
Member